Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Brain zap trial aims to sharpen thinking in schizophrenia

NCT ID NCT06003036

Knowledge-focused Sponsor: Deepak K. Sarpal, M.D. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Aug 11, 2026 · Updated 3 times

Summary

This study tests whether a fast form of brain stimulation (accelerated iTBS) can improve thinking and memory in 30 adults with schizophrenia or schizoaffective disorder who are already taking the medication clozapine. Participants will receive both real stimulation and a sham (fake) version in a random order, while their brain activity is measured with MRI. The goal is to see if the stimulation changes brain connections linked to working memory.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
transcranial magnetic stimulation (accelerated intermittent theta burst stimulation)
What this could lead to
If it works, this could point toward a non-drug way to boost thinking and memory in people with schizophrenia who are already on clozapine.
What could go wrong
This is a very small, early study (30 people) looking at brain scans, not symptoms. It may not lead to any real-world benefit, and the effects could be temporary or no different from sham.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

30 people

The number who actually took part.

Started

Dec 2023

Finished

Jan 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. A current Diagnostic and Statistical Manual of Mental Disorders 5 (DSM 5)-defined diagnosis of schizophrenia or schizoaffective disorder 2. age 18-65 years 3. at least 4 months of clozapine treatment 4. history of at least 2 failed antipsychotic trials 5. competency and willingness to sign informed consent 6. A clinically optimized dosage of clozapine, unchanged for at least 1 month, with a minimum of 150 mg/day Exclusion Criteria: 1. Serious neurologic or medical condition/treatment that impacts the brain 2. a significant risk of suicidal or homicidal behavior 3. cognitive or language limitations, or any other factor that would preclude subjects providing informed consent 4. pregnancy or postpartum (\<6 weeks after delivery or miscarriage) 5. history of treatment with electroconvulsive therapy 6. contraindications for magnetic resonance imaging (e.g., a pacemaker) 7. Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders 5 (DSM 5)-verified moderate or severe substance use disorder, including alcohol use disorder 8. seizure disorder or prior history of seizures on clozapine 9. patients taking both bupropion and clozapine 10. prior issues with intermittent theta burst stimulation/transcranial magnetic stimulation administration Concomitant treatment with serotonin and norepinephrine reuptake inhibitors will be examined on a case-by-case basis.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Schizoaffective disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Psychotic Disorders schizoaffective disorder schizophrenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Schizoaffective disorder Schizophrenia

Contacts and locations

Locations

  • UPMC Western Psychiatric Hospital/University of Pittsburgh

    Pittsburgh, Pennsylvania, 15213, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.